Chemical clears Alzheimer's protein and restores memory in mice

December 9, 2015, Alzheimer's Research UK
Diagram of the brain of a person with Alzheimer's Disease. Credit: Wikipedia/public domain.

A research team in Korea has tested a chemical in mice genetically altered to develop features of Alzheimer's, showing it can remove a build-up of protein in the brain associated with the disease as well as rescuing memory and behaviour problems in the animals. The findings are published in the journal Nature Communications on Tuesday 8 December 2015.

Alzheimer's disease is associated with many abnormal changes in the , including the build-up of hallmark proteins amyloid and tau, activation of the immune system and a breakdown in communication between nerve cells. Amyloid is a protein that is normally present in the brain but behaves abnormally in Alzheimer's, often many years before symptoms show. This abnormal amyloid is sticky and starts to clump together into larger and larger structures – eventually creating large 'plaques' that are visible in the brain under a microscope.

Researchers at the Korea Institute of Science and Technology had previously discovered a set of molecules that could either speed up or slow down the formation of amyloid plaques in test tubes in the laboratory. In this study, they explored the effect of one of these compounds – 4-(2-hydroxyethyl)-1-piperazinepropanesulphonic acid (EPPS) – in mice showing features of Alzheimer's.

In the first experiment, the team found that administering EPPS to mice in either before, or at the same time as, the mice were injected with abnormal amyloid protein could rescue problems with memory caused by the protein in the brain. The researchers report that EPPS was not toxic to rodents at the doses used and was able to cross into the brain – a particular challenge when developing new drugs for diseases like Alzheimer's.

In a second experiment, the researchers gave EPPS to mice genetically engineered to develop a build-up of amyloid in the brain, to model what is seen in human disease. These mice start to develop amyloid plaques in the brain and show problems with memory and behaviour which get progressively worse over time. In contrast to some other studies, which treat animals before the disease has started to take hold, the researchers waited until the mice had developed large amounts of amyloid plaques in the brain and severe memory problems before treating them with EPPS in drinking water for three months.

The results showed that treatment with EPPS improved the performance of the mice in tests of memory and learning compared to untreated animals or healthy mice treated with EPPS. Examination of the brains of the mice showed that EPPS had cleared amyloid plaques from the brain and that this difference was greater in animals that had been treated with higher doses of the chemical. Mice treated with EPPS also showed fewer signs of inflammation in the brain.

When the researchers carried out detailed studies of how EPPS was working in laboratory tests, they found evidence that that the chemical could bind directly to clumps of amyloid, breaking them down even at an when they were first starting to stick together.

Dr Simon Ridley, Director of Research at Alzheimer's Research UK, said:

"There is currently a strong focus on developing treatments for Alzheimer's that aim to stop the build-up of the hallmark Alzheimer's protein, amyloid, in the brain. Although some anti-amyloid drugs are currently in late-stage clinical testing, several trials have also failed and there is much debate as whether this is a suitable approach for a new treatment. Many of the current drugs being explored act to stop the formation of in the brain which mean they may need to be given early in the disease process.

"This interesting study in uses a chemical able to break down Alzheimer's plaques in the brain after they've already formed, potentially presenting a way to circumvent the difficult issue of timing with this treatment approach. While this is an appealing prospect, the research is still at the early stage of being explored in animals. Research in animals is an important step in developing any new treatment, but we'll need to see the findings translated into clinical studies in people before we could know the potential of EPPS to treat Alzheimer's in humans.

"With no new treatments for Alzheimer's licensed since 2002, we urgently need to capitalise on promising early science to make sure it's progressed as quickly as possible towards clinical testing. Alzheimer's Research UK has launched several large initiatives, including our Drug Discovery Alliance, to ensure that positive early findings can be moved towards new treatments for diseases like Alzheimer's more quickly."

Explore further: Synapse discovery could lead to new treatments for Alzheimer's disease

Related Stories

Synapse discovery could lead to new treatments for Alzheimer's disease

November 27, 2015
A team of researchers led by UNSW Australia scientists has discovered how connections between brain cells are destroyed in the early stages of Alzheimer's disease - work that opens up a new avenue for research on possible ...

Engineered protein prevents dementia in mice carrying Alzheimer's genes

October 21, 2015
A newly developed protein has successfully prevented dementia from occurring in lab mice carrying human Alzheimer's genes, raising the possibility for development of new treatments for the disease.

Can slow walking speed in elderly signal Alzheimer's disease hallmarks?

December 2, 2015
How fast elderly people walk may be related to the amount of amyloid they have built up in their brains, even if they don't yet have symptoms of Alzheimer's disease, according to a study published in the December 2, 2015, ...

Researchers target immune system in hunt for new Alzheimer's treatments

August 19, 2015
Researchers in Israel have manipulated the mouse immune system to target Alzheimer's disease. The research was published in the journal Nature Communications on 18 August 2015.

Two amyloid-beta antibodies found to cause neuronal dysfunction in mice

November 10, 2015
(Medical Xpress)—A team of researchers working in Germany has found that giving two different types of amyloid-β antibodies to mice genetically engineered to have Alzheimer's type symptoms caused them to develop a type ...

Neuroscientists gain insight into cause of Alzheimer's symptoms

November 23, 2015
Virginia Tech Carilion Research Institute scientists have uncovered a mechanism in the brain that could account for some of the neural degeneration and memory loss in people with Alzheimer's disease.

Recommended for you

Meditation and music may alter blood markers of cellular aging and Alzheimer's disease

November 13, 2018
A research team led by Dr. Kim Innes, a professor in the West Virginia University School of Public Health, has found that a simple meditation or music listening program may alter certain biomarkers of cellular aging and Alzheimer's ...

Alzheimer's and cardiovascular disease share common genetics in some patients

November 9, 2018
Genetics may predispose some people to both Alzheimer's disease and high levels of blood lipids such as cholesterol, a common feature of cardiovascular disease, according to a new study by an international team of researchers ...

Artificial intelligence predicts Alzheimer's years before diagnosis

November 6, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer's disease, according to a study published in the journal Radiology.

Diabetes medications may reduce Alzheimer's disease severity

November 1, 2018
People with Alzheimer's disease who were treated with diabetes drugs showed considerably fewer markers of the disease—including abnormal microvasculature and disregulated gene expressions—in their brains compared to Alzheimer's ...

Massive study confirms that loneliness increases risk of dementia

October 29, 2018
A new Florida State University College of Medicine study involving data from 12,000 participants collected over 10 years confirms the heavy toll that loneliness can take on your health: It increases your risk of dementia ...

Bioactive compound from the Rhodiola plant improves memory

October 25, 2018
In an ageing society, more people are suffering from memory disorders. The progressive loss of memory severely impairs the quality of life of those affected. So far, no drugs are known to prevent age-related cognitive decline.


Adjust slider to filter visible comments by rank

Display comments: newest first

5 / 5 (1) Dec 09, 2015
"THC blocks an enzyme called acetylcholinesterase, which speeds the formation of amyloid plaque in the brains of people with Alzheimer's disease. The Alzheimer's drugs Aricept and Cognex work by blocking acetylcholinesterase. When tested at double the concentration of THC, Aricept blocked plaque formation only 22% as well as THC, and Cognex blocked plaque formation only 7% as well as THC." From "Marijuana May Slow Alzheimer's" WebMD.

And, when THC activates the CB2 receptors- "The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages" and "Activation of the CB(2) receptor system reverses amyloid-induced memory deficiency" (both at PubMed).

So THC from cannabis prevents the deposit of amyloid plaque and tells your clean-up crew cells (macrophages) to remove the plaque, thus restoring memory! FYI- Cannabis is very easy to grow outdoors!
5 / 5 (1) Dec 09, 2015
Current agonist being used in trials by Anavex works on upstream approach, also Anavex`s agonist is working on the other hallmarks of AD first inflammation and ocedative(sp?) stress on the mitochondria.Thru P1 clean profile,patients and caretakers asked for extension of trials as the progress has been characterized like a switch from night to day.
not rated yet Dec 09, 2015
Inhibiting or removing amyloid beta is not the answer!!! They proved in a study that by doing so will actually create dementia in humans.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.